APTOSE BIOSCIENCES INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.66 CAD | -1.19% |
|
-1.78% | -50.45% |
Presentation Operator MessageOperator (Operator)Good afternoon. My name is [ Shandrelin ], and...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Aptose Biosciences Inc. is a clinical-stage biotechnology company. The Company is engaged in the development and commercialization of precision medicines addressing unmet clinical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage oral kinase inhibitors under development for hematologic malignancies: tuspetinib (HM43239), an oral, myeloid kinase inhibitor being studied as monotherapy and in combination therapy in the APTIVATE international Phase I/II expansion trial in patients with relapsed or refractory acute myeloid leukemia (AML); and luxeptinib (CG-806), an oral, dual lymphoid and myeloid kinase inhibitor in Phase I a/b stage development for the treatment of patients with relapsed or refractory hematologic malignancies.
Calendar
2024-05-13
- Q1 2024 Earnings Release
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.68
Average target price
-
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -50.45% | 19.33M | |
| +22.59% | 44.96B | |
| +1.14% | 42.65B | |
| +45.77% | 41.85B | |
| -4.27% | 29.04B | |
| +11.18% | 26.08B | |
| -21.36% | 19.03B | |
| +6.59% | 12.75B | |
| +28.34% | 12.06B | |
| -4.09% | 11.75B |
- Stock Market
- Equities
- APS Stock
- News Aptose Biosciences Inc.
- Transcript : Aptose Biosciences Inc., Q3 2022 Earnings Call, Nov 01, 2022